MBB, the pipeline Is one in thousands across the country and it creates jobs!
There isn't to much more than the liberal spin against it so you can stay right there MBB on your fat tail bone and spin all you want for your boy in the white house.
MBB you said it more that once but I have no energy to look back, maybe someone else will.
I know you said you have a long position, Great!
but you have been playing the stock short for the past year.
Good luck with those 100 long shares.
Generally there is a holding period in stock offerings. Considering the fact that the stock is being accumulated by walls street, it's likely these shares are going into long term holdings in similar buyers.
Often the pros will hedge by shorting, puts or various other strategies so those positions may rise.
Makes no difference, the stock will rise sooner than later.
Sentiment: Strong Buy
don't buy into the short dilution cry of the shorts. Biotech lives on selling stock. It's a part of the business. Would we be better off if they did what EXEL did? no way. Worse yet, license out their drugs?
All of the 3 digit priced Biotechs achieved their lofty prices by maintaining their assets in house. A.M. knows exactly what he is doing.
See you well over $100!
Sentiment: Strong Buy
Phase 3 continues.
From my experience owning Biotech which early approval was issued, the FDA allowed the marketing while the phase 3 continued. SGEN's ACETRIS went this route.
Mbb you commented in the past that CLDX would go below $10 before it saw $20 again so the kettle calling the pot black?
Great, after listrning to the conference this morning, the tone definitely supported the move. AM also said keeping the assets in house was the best way to create shareholder value and he is absolutely right.
MBB your boy said he was going to veto it because it doesn't do anything for America.
the rest of your post is just more BS.
There was a discussion that put the potential Varli franchise in excess of 8 billion market. That put the drug in a very exclusive group of drugs like Lipitor.
IMO $200 is cheap under those circumstances.
they left the door open for a possible stock issue but as AM said, the value to stockholders is in keep the franchise in house instead of licencing out the future to some other company for pennies on the dollar.
Zacks never gives the thumbs up on these types of Biotechs. Their evaluation model screens for earnings and return on investment and we all know the value is in the pipeline.